Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience

Sabrina Chiloiro, Antonella Giampietro, Irene Gagliardi, Marta Bondanelli, Miriam Veleno, Maria Rosaria Ambrosio, Maria Chiara Zatelli, Alfredo Pontecorvi, Andrea Giustina, Laura De Marinis, Maria Chiara Zatelli, Alfredo Pontecorvi, Andrea Giustina, Laura De Marinis, Maria Chiara Zatelli, Alfredo Pontecorvi, Andrea Giustina, Laura De Marinis

Accepted: 21 July 2022 / Published online: 3 August 2022 © The Author(s) 2022

Abstract

Introduction Acromegaly is a chronic disease with systemic complications. Disease onset is insidious and consequently typically burdened by diagnostic delay. A longer diagnostic delay induces more frequently cardiovascular, respiratory, metabolic, neuropsychiatric and musculoskeletal comorbidities. No data are available on the effect of diagnostic delay on skeletal fragility. We aimed to evaluate the effect of diagnostic delay on the frequency of incident and prevalent vertebral fractures (i-VFs and p-VFs) in a large cohort of acromegaly patients.

Patients and methods A longitudinal, retrospective and multicenter study was conducted on 172 acromegaly patients.

Results Median diagnostic delay and duration of follow-up were respectively 10 years (IQR: 6) and 10 years (IQR: 8). P-VFs were observed in 18.6% and i-VFs occurred in 34.3% of patients. The median estimated diagnostic delay was longer in patients with i-VFs (median: 11 years, IQR: 3), in comparison to those without i-VFs (median: 8 years, IQR: 7; p = 0.02). Age at acromegaly diagnosis and at last follow-up were higher in patients with i-VFs, with respect to those without i-VFs. The age at acromegaly diagnosis was positively associated with the diagnostic delay (p < 0.001, r = 0.216). A longer history of active acromegaly was associated with a high frequency of i-VFs (p = 0.03). The logistic regression confirmed that patients with a diagnostic delay > 10 years had 1.5-folds increased risk of developing i-VFs (OR: 1.5; 95%CI: 1.1–2; p = 0.017).

Conclusion Our data showed that the diagnostic delay in acromegaly has a significant impact on VF risk, further supporting the clinical relevance of an early acromegaly diagnosis.

Keywords Vertebral fractures · Skeletal fragility · GH secreting adenoma · GH · IGF-1 · Osteomalacia

Introduction

Acromegaly is a clinical syndrome characterized by growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess. Chronic excess of GH and IGF-1 induces progressive somatic changes and is associated with multiple complications as cardiovascular, respiratory, metabolic, neoplastic, musculoskeletal disease, that are responsible for increased mortality and compromised quality of life [1–3]. The musculoskeletal disease in acromegaly includes secondary osteoarthritis and skeletal fragility with an increased risk of vertebral fractures (VF) [4]. VFs involve around 25–40% of acromegaly patients [5]. Several studies investigated the risk factors for the occurrence of VFs, identifying as the most significant the higher levels of GH and IGF-1, the longer length of biochemically active disease and the presence of pre-existing VFs [2, 4–10].

As the clinical features of acromegaly develop insidiously, the diagnosis is often significantly delayed [11]. The diagnostic delay in acromegaly ranges from 2 to 25 years [12, 13]. Data from the Swedish National Patient Registry on 603 acromegaly patients showed that 23% of patients had a
diagnostic delay from 1 to 5 years, the 17% of patients had a
diagnostic delay from 5 to 10 years and up to 24% of patients
had a diagnostic delay over than 10 years [14]. Moreover,
patients with a longer diagnostic delay were affected more
frequently by cardiovascular, respiratory, metabolic, neu-
ropsychiatric and musculoskeletal comorbidities. An early
diagnosis and a proper treatment can prevent the develop-
ment of irreversible complications of the disease, improving
in parallel the patients’ quality of the life [15].

Since data on the impact of the diagnostic delay on the
occurrence of VFs in acromegaly are not yet available, we
aimed to investigate the effect of the diagnostic delay on
the prevalence and incidence of VFs, in a multicenter and
retrospective large cohort of acromegaly patients.

**Patients and methods**

A longitudinal, retrospective, observational and multicenter
study was performed on acromegaly patients. All patients
were consecutively enrolled according to the following
inclusion and exclusion criteria.

**Inclusion criteria were**

1. diagnosis of acromegaly;
2. age older than 18 years;
3. patients attending out-patient Pituitary clinics;
4. availability of sequential spine X-ray evaluations at least
   at acromegaly diagnosis and at last evaluation visit;
5. last endocrine evaluation conducted within the last
   12 months.

The exclusion criteria were:

1. diagnosis of active neoplastic disease;
2. diagnosis of primary hyperparathyroidism and MEN-1
   syndrome;
3. untreated hyperthyroidism
4. use of bone active drugs (except calcium and vitamin D)
   in the 12 months prior to study entry (acromegaly
diagnosis);
5. treatment with drugs known to cause fragility fractures
   (16) with the exception of glucocorticoid replacement
   therapy for hypopituitarism;
6. history of spine surgery.

**Objectives**

The primary objective of the study was to evaluate the asso-
ciation between the diagnostic delay in acromegaly and both
the prevalence of VFs at acromegaly diagnosis and the inci-
dence of VFs, during the follow-up.

As secondary objectives, we evaluated the correlations
between incident VFs and (1) activity of acromegaly at
the end of follow-up, (2) duration of active disease, (3)
IGF-1 and GH values during follow-up, (4) prevalent VFs
at the acromegaly diagnosis, (6) hypopituitarism status,
(7) patients’ gender, (8) treatment for osteoporosis and
acromegaly.

All the clinical information were retrospectively collected
by the medical records of the patients.

**Evaluation of acromegaly**

Acromegaly was diagnosed according to guidelines available
at the time of the first observation of the patients. During
the follow-up, acromegaly patients underwent periodical
evaluation of GH and IGF-1, to define the control of the dis-
ease. According to disease status, patients were classified as
cured, controlled or affected by active disease. Acromegaly
was defined:

– cured in patients off-therapy for at least six consecutive
  months with normal age and gender-adjusted IGF-1 val-
  ues and random/integrate GH was below 1.0 ng/mL and
  with GH nadir < 0.4 ng/mL during oral glucose tolerance
  test (OGTT) in not-diabetic patients;
– controlled in patients treated with medical therapy, with
  normal age and gender-adjusted IGF-1 values and ran-
  dom GH was below 1.0 ng/mL [17];
– active in patients treated with medical therapy, IGF-1
  concentrations above the normal ranges for age and gen-
  der, and with random GH higher than 1.0 ng/mL [18].

Patients on treatment with Peg-V were evaluated only by
serum IGF-1 [18]. IGF-1 was expressed according to upper
limit of normal (ULN), based on normative data for each
center laboratory.

According to the consensus of acromegaly [17], during
the follow-up, the IGF-1 levels reflect the clinical activity
of the disease. Serum GH levels can be used to assess the
control. In patients with discrepant levels of GH and IGF-1,
the consensus recommend relying on IGF-1 values, after
making sure on the use of well-validated IGF-1 assay and
after ruling out pre-analytic and analytical confounding
factors [17], such as malnutrition, obesity, eating disorders,
poorly controlled diabetes mellitus, cystic fibrosis, hepatic
and renal disease, hypothyroidism, hyperthyroidism, sepsis,
supraphysiological testosterone replacement [19].

The diagnostic delay was defined as the number of years
between the time of ascertained acromegaly diagnosis and
the presumed time of occurrence of the first acromegaly
related symptoms. The length of active acromegaly was esti-
imated as the number of months between the time of reaching
two consecutive values of IGF-1 within the normal ranges for age and gender and the time of acromegaly diagnosis.

**Definition of diagnostic delay**

The diagnostic delay was calculated as the elapsed time between the date of the first reported comorbidity and the date of acromegaly diagnosis, as recently reported by Esposito et al. [14]. The date of diagnosis was defined as the first specialized healthcare visit or admission with acromegaly diagnosis. The date of onset of the first comorbidity was defined as the first registration of any predefined comorbidity from medical records. The more specific acromegaly associated comorbidities were taken in account, such as visual-field defects, headache, hypopituitarism, arthropathy, osteoporosis, vertebral fractures, non-traumatic fractures, carpal tunnel syndrome, macroglossia, hypertension, cardiomyopathy, cardiac hypertrophy/heart disease, heart failure, cardiac dysrhythmia, ischemic heart disease, sleep apnea, diabetes, impaired glucose tolerance, second benign and malign tumors, nodular thyroid disease, polyps of colon and of vocal cord and larynx [14] (see Fig. 1).

**Evaluation of vertebral fractures**

Prevalent and incident vertebral fractures (VFIs) were investigated respectively on spine X-rays performed at acromegaly diagnosis and at last visit, using quantitative morphometric approach, as previously described [6]. Anterior (Ha), middle (Hm), and posterior (Hp) vertebral heights were measured and height ratios were calculated for each vertebra from T4 to L4. Prevalent VFIs were identified on the baseline radiographs, whereas incident VFIs were identified on spinal radiographs obtained at the follow-up, and they were defined as a decrease of 20% or more and at least 4 mm in length in any of the three vertebral heights (Ha, Hm, or Hp) compared with the baseline radiograph. As for clinical practise at our Pituitary divisions and according to 2013 guidelines on the management of comorbidities in acromegaly [20], vertebral morphometry on thoracic and lumbar spine x-ray is conducted at the time of acromegaly diagnosis and every two years, during follow-up.

**Statistical analysis**

The patients’ cohort was described in its clinical and demographic features using descriptive statistics techniques. Normality of continuous variables was checked using Kolmogorov–Smirnov test. Quantitative variables were expressed as median and range and qualitative variables as absolute and percentage frequency. Chi square test (or Fisher exact test when necessary) and Mann Whitney non-parametric tests were used to compare categorical and quantitative un-paired data. The variables that reached the statistical significance at the univariate analysis entered the logistic regression. The analyses were performed using SPSS software version 24.0 for Windows.

**Results**

A total of 172 patients entered the study, from an initial cohort of 187 cases (10 cases were excluded for the absence of sequential spine X-ray evaluations and 5 patients were excluded as considered lost at follow-up, as last evaluation was conducted over 12 months).
Among the study cohort, 91 patients were females (52.9%). Median age at ACRO-diagnosis was 42.5 years (IQR: 19). Median estimated diagnostic delay was of 10 years (IQR: 6).

Thirty-two patients were bearing VFs already at ACRO-diagnosis (18.6%). Among the 140 patients without VFs at ACRO-diagnosis, 48 patients developed new vertebral fractures (34.3% of cases p < 0.001) during follow-up. Among the 32 patients with prevalent VFs, 15 patients developed new incident VFs during the follow-up (46.9% of cases).

Median duration of follow-up was 10 years (IQR: 8). During follow-up, 121 patients (70.3%) received vitamin D3 and consequently none case of secondary hyperparathyroidism was detected. Doses of vitamin D ranges from 500 to 3300 units per day; ten patients (5.5%) underwent treatment with bone active drugs.

At last follow-up visit, fifty-five patients (31.9%) were considered cured after pituitary surgery and/or after six consecutive months from the discontinuation of medical therapy. One-hundred three patients (59.9%) were considered controlled during medical therapies and 14 patients (8.2%) were considered affected by active acromegaly. In this study cohort, five patients were considered affected by active acromegaly with discordant GH and IGF-1 levels. These patients carried in at least two consecutive hormonal assessments random GH < 1 ng/mL and IGF-1 upper the age and gender-adjusted range of normality. After ruling out the causes of discrepant levels of GH and IGF-1 (such as physical exercise, pregnancy, hypothyroidism and hyperthyroidism) [19], the patients were considered affected by active acromegaly, also in accordance with the persistence of symptoms of active acromegaly.

Vertebral fractures at acromegaly diagnosis

As showed in Table 1, among the whole study population, the prevalence of vertebral fractures at ACRO-diagnosis did not differ according to gender, age, GH and IGF-1 value at acromegaly diagnosis, smoking, alcohol abuse, gonadal function, central hypoadrenalism and dosage of hydrocortisone or equivalent corticosteroids.

Vertebral fractures during follow-up

As showed in Table 1, the occurrence of incident vertebral fractures associated with the diagnostic delay. In fact, the median estimated diagnostic delay was significantly longer in patients with incident VFs (median 11 years, IQR: 3), in comparison to the diagnostic delay evaluated for patients without.

Incident VFs (median 8 years, IQR: 7; p=0.02). As showed in Fig. 2, the incidence of VFs progressively increased with a longer diagnostic delay: incidental VFs occurred in 5.3% of patients with a diagnostic delay shorter than 5 years, in 21.1% of patients with a diagnostic delay shorter than 10 years and in 73.7% of patients with a diagnostic delay longer than 10 years (p=0.01). The area under the ROC curve developed for the estimated diagnostic delay was 0.68 (95% CI 0.5–0.82; p = 0.04), as showed in Fig. 2. Optimal cut-off value of diagnostic delay for predicting the risk of incident vertebral fractures was over 10 years (specificity: 90.9% sensitivity: 74%).

We found that patients who experienced incident VFs were older than those without VFs both at the time of acromegaly diagnosis, both at the time of the diagnosis of incident VFs and, at last follow-up. Anyway, we found a positive correlation between the age of patients at the acromegaly diagnosis and at the time of the diagnosis of incident VFs (p<0.001, r=0.841) and between the age of patients at the acromegaly diagnosis and the age of patients at last follow-up (p<0.001, r=0.951), as showed in Fig. 3. In particular, the median age at acromegaly diagnosis was 45 years (IQR: 22) in patients with incident VFs and of 38 years (IQR: 20 p=0.04) in patients without incident VFs. Interestingly, we found a positive correlation between the age at acromegaly diagnosis and the diagnostic delay (p<0.001, r=0.216), as showed in Fig. 4. Moreover, we found that patients with incident VFs were older (median age at last follow-up 61.3 years IQR: 13) as compared to patients without incident VFs (median age at last follow-up 52 years IQR: 13, p<0.001), also at last follow-up. A positive correlation between age at last follow-up and diagnostic delay was identified (p<0.001, r=0.466). No gender difference in the incidence and prevalence of VFs was observed.

A longer length of active acromegaly was associated with the development of VFs during follow-up (p=0.03): median duration of active acromegaly was 60 months (IQR: 58) in patients with incident VFs and 36 months in patients without VFs (IQR: 56; p=0.03).

Logistic regression

Age at acromegaly diagnosis, at the time of diagnosis of incident VFs and at last follow-up in the whole cohort and in females, diagnostic delay and length of active acromegaly entered the logistic regression. As shown in Table 2, the logistic regression showed that the only determinant for the event incident vertebral fractures was the diagnostic delay longer than 10 years. Patients with a diagnostic delay over 10 years had a 1.5-fold increased risk for developing incident VFs (OR: 1.5; 95%CI: 1.1–2; p=0.017).
Discussion

The diagnostic delay in acromegaly has recently emerged as a relevant clinical issue, resulting in increased mortality and frequency of metabolic, musculoskeletal and cardiovascular comorbidities [21].

In this study, we describe the relevant impact of the diagnostic delay on acromegalic osteopathy in a retrospective and longitudinal cohort of 172 patients, in whom were analysed both the prevalence of VFs at acromegaly diagnosis and the incidence during a follow-up of 10 years.

In this multi-center cohort, we found a prevalence of VFs of 18.6% and an incidence of 34.3%. These data are in line with previous studies that reported a VF’s prevalence ranging from 32 to 42% and an incidence ranging from 26 to 35% [7, 22–26].

The determinants of skeletal fragility in acromegaly are not yet completely clarified, despite several published studies. Until now, high levels of GH and IGF-1, the persistence of active acromegaly despite therapies, the untreated hypogonadism, the overtreated central hypoadrenalism were recognized as risk factors for skeletal fragility in acromegaly [7, 20–27].

It is well known that the GH and the IGF-1 act as regulators of the bone homeostasis. GH promotes the osteoblastogenesis and the chondrogenesis and inhibits the

| Table 1 | Skeletal fragility at acromegaly diagnosis and during follow-up. §: 140 patients that were not diagnosed for skeletal fragility at the time of acromegaly diagnosis, *: among 100 patients without skeletal fragility at acromegaly diagnosis and on medical treatment at the end of the study |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Prevalent vertebral fractures at ACRO-diagnosis Yes | No | p-value | Yes | No | p-value |
| Age at ACRO diagnosis median, (IQR) | 41 (20) | 47 (15) | 0.87 | 45 (22) | 38 (20) | 0.04 |
| Estimated diagnostic delay median years, (IQR) | 10.5 (10.5) | 10 (6) | 0.57 | 12 (2) | 9 (7) | 0.02 |
| Gender | | | | | | |
| Females n, (%) | 19 (59.4%) | 72 (51.4%) | 0.42 | 30 (62.5%) | 50 (54.3%) | 0.06 |
| Males n, (%) | 13 (40.6%) | 68 (48.6%) | 0.43 | 18 (37.5%) | 42 (45.7%) | 0.07 |
| GH at ACRO diagnosis median, (IQR) | 4 (7) | 6 (8) | 0.37 | 6 (7) | 3.4 (7) | 0.67 |
| IGF-I x ULN at ACRO diagnosis median, (IQR) | 2.7 (0.5) | 2.4 (1.5) | 0.37 | 2.3 (1.4) | 2.4 (2) | 0.74 |
| Central hypoadrenalism | | | | | | |
| Yes n, (%) | 14 (43.8%) | 55 (39.3%) | 0.62 | 19 (39.6%) | 36 (39.1%) | 0.96 |
| No n, (%) | 18 (56.3%) | 85 (60.7%) | 0.62 | 29 (60.4%) | 56 (60.9%) | 0.07 |
| Dosage of hydrocortisone (or equivalent) | | | | | | |
| Patient treated with ≤ 20 mg/daily n, (%) | 10 (71.4%) | 36 (65.5%) | 0.67 | 13 (68.4%) | 23 (63.9%) | 0.74 |
| Patient treated with > 20 mg/daily n, (%) | 4 (28.6%) | 19 (34.5%) | 0.67 | 6 (31.6%) | 13 (36.1%) | 0.74 |
| Gonadal function | | | | | | |
| Normal n, (%) | 25 (78.1%) | 105 (75%) | Ref | 32 (66.7%) | 73(79.3%) | Ref |
| Treated central hypogonadism n, (%) | 0 (0%) | 0 (0%) | Na | 3 (6.3%) | 15 (16.3%) | 0.23 |
| Untreated central hypogonadism n, (%) | 4 (18.2%) | 21 (15%) | 0.9 | 2 (4.2%) | 1 (1.1%) | 0.18 |
| Menopause n, (%) | 3 (9.4%) | 14 (10%) | 0.8 | 11 (22.9%) | 3 (3.3%) | 0.001 |
| Acromegaly outcome | | | | | | |
| Cured/controlled n, (%) | Na | Na | Na | 45 (93.8%) | 83 (90.2%) | 0.48 |
| Active n, (%) | Na | Na | Na | 3 (6.3%) | 9 (9.8%) | 0.8 |
| GH at follow-up median, ng/mL, (IQR) | Na | Na | Na | 1 (1.3) | 0.6 (2) | 0.8 |
| IGF-I x ULN at follow-up median, (IQR) | Na | Na | Na | 0.6 (1.4) | 0.8 (0.3) | 0.15 |
| Length of active acromegaly median months, (IQR) | Na | Na | Na | 60 (58) | 36 (56) | 0.03 |
| Medical treatment (*) | | | | | | |
| First generation somatostatin analogues n, (%) | Na | Na | Na | 26 (74.3%) | 38 (60.3%) | Ref |
| Dopamine agonist n, (%) | Na | Na | Na | 2 (5.7%) | 2 (3.2%) | 0.24 |
| Pegvisomant n, (%) | Na | Na | Na | 6 (17.1%) | 20 (31.7%) | 0.11 |
| Pasireotide Lar n, (%) | Na | Na | Na | 2 (5.7%) | 2 (3.2%) | 0.24 |
| Pasireotide Lar plus Pegvisomant n, (%) | Na | Na | Na | 1 (2.9%) | 1 (1.6%) | 0.27 |
| Bone active drugs, n (%) | Na | Na | Na | 3 (30%) | 7 (70%) | 0.589 |
adipogenesis. GH stimulates also, either directly or indirectly through IGF-1, the function of mature osteoblasts, through the carboxylation of osteocalcin, which impairs osteoclastogenesis [28, 29]. On mature osteoblasts, IGF-1 up-regulates type I collagen transcription and decreases the synthesis of matrix metalloproteinase 13, a collagen-degrading protease [30]. Indirectly, IGF-1 promotes osteoblastogenesis by the stabilization of the β-catenin, a signaling molecule of the wnt canonical signaling pathway, which is essential for osteoblastogenesis [31, 32]. The function of IGF-1 on osteoclasts is less clear. IGF-1 may induce osteoclastogenesis through the ligand of the activator receptor of nuclear factor kB (RANK-L), although this effect is tempered by the production of osteoprotegerin mediated by GH [33, 34].

A longer time of exposure to GH and IGF-1 hypersecretion was also associated to skeletal fragility in acromegaly and to an increased risk of VFIs. The long term exposure to GH and IGF-1 in acromegaly may be due both to the persistence of active disease and both to the diagnostic delay. Taking into account the impact of GH and IGF-1 hypersecretion on the occurrence of systemic complications (as cardiovascular, respiratory, metabolic, neoplastic and musculoskeletal ones), several studies had underlined the importance of an early achievement of normalization of GH and IGF-1 levels. Recently, the longer diagnostic delay was recognized as a risk factor for the occurrence on musculoskeletal, cardiovascular, respiratory, metabolic, oncological and neuropsychiatric comorbidities in acromegaly [14].

In parallel, our study discloses that a long diagnostic delay is a clinical significant risk factor for the occurrence of skeletal fragility and VFIs. We found that the occurrence of incident VFIs during follow-up was more frequent in acromegaly patients with a longer diagnostic delay. Our data can suggest a cumulative effect over time of the GH and IGF-1 hypersecretion on bone homeostasis, possibly explaining the effect of acromegaly diagnostic delay on the incidence of VFIs rather than on their prevalence. In fact, to our knowledge, this study described for the first time that a diagnostic delay longer than 10 years is associated with an increased incidence of VFIs, which were previously reported to be associated to a reduced quality of life and to the presence of systemic complications.

Fig. 2 Roc Curve. The area under the ROC curve developed for the month of diagnostic delay in patients who developed incident vertebral fractures was 0.68 (95% CI 0.5–0.82; p = 0.04), as showed in Fig. 2. Optimal cut-off was identified at 10 years (specificity: 90.9% sensitivity: 74%)

Fig. 3 Scatter plot correlating in a the age of patients at the acromegaly diagnosis and at the time of the diagnosis of incident VFIs (p < 0.001, r = 0.841) and in b the age of patients at the acromegaly diagnosis and the age of patients at last follow-up (p < 0.001, r = 0.951)
of hyperkyphosis [35, 36]. In fact, thoracic hyperkyphosis may impair the cardiorespiratory function and predispose to worse outcome of pulmonary infections such as COVID-19 [37].

In addition, we found that patients without VFs at acromegaly diagnosis had a low frequency of incident vertebral fractures during the follow-up. Conversely, patients who carried VFs at acromegaly diagnosis had a 1.5 fold increased risk for the occurrence of new vertebral fractures during the follow-up. These data suggest that the skeletal fragility may be considered a relatively early complication of acromegaly disease, confirming data reported at the time of neurosurgery [8].

The early onset and the irreversibility of VFs requires strict screening and surveillance protocols since the time of acromegaly diagnosis [38, 39], that includes the assay of markers of bone formation and resorption, calcium, vitamin D and parathyroid hormone (PTH), the vertebral morphometry and possibly the analysis of bone microstructure though the trabecular bone score (TBS) and the microindentation technique [40]. In addition, the vitamin D supplementation and the prescription of bone active drugs may improve the bone quality in acromegaly patients, in particular in those with active disease, together with the early normalization of GH and IGF-1 levels [25].

Despite VFs are rarely diagnosed clinically in acromegaly patients for their subclinical and not-specific onset symptoms (such as back pain) [41], VFs are considered a clinical relevant issue. VFs reflect the bone health. The occurrence of VFs affects the quality of life and the overall survival of the patients [35–37]. For all these reasons, according to 2013 and 2020 guidelines on the management of comorbidities in acromegaly patients [20, 39], we routinely performed in our clinical practise a spine X-ray with morphometry, at acromegaly diagnosis and every two years, during the follow-up. Interestingly, the last guidelines on 2020 for acromegaly comorbidities suggested an annual screening with vertebral morphometry on thoracic and lumbar spine x-ray in acromegaly patients at high risk for the occurrence of VFs, as those with history of non-traumatic or vertebral fractures, osteopenia/osteoporosis, kyphosis, untreated hypogonadism and biochemical active acromegaly [39]. The vertebral morphometric approach has been widely recognized as the “gold standard” for the evaluation of bone health in acromegaly [9]. The dual-energy X-ray absorptiometry (DXA) leads to inconsistent densitometry results, for the variable distribution of trabecular and cortical bones in the different skeletal sites, for the abnormalities of bone structures, osteophytes, face-joint hypertrophy, increased periosteal ossification and bone enlargement in acromegaly [10]. More recently, if the

---

**Table 2** Logistic regression for the occurrence of incident vertebral fractures during acromegaly follow-up

|                         | p-value | OR (95%CI)   |
|-------------------------|---------|--------------|
| Age at acromegaly diagnosis | 0.676   | Na           |
| Menopause               | 0.99    | Na           |
| Diagnostic delay        | 0.008   | 1.5 (1.1–2)  |
| Length of active acromegaly | 0.428   | Na           |
| Age at the diagnosis of incident VFs | 0.432   | Na           |
| Age at last follow-up   | 0.175   | Na           |

---

**Fig. 4** Scatter plot correlating age at acromegaly diagnosis and diagnostic delay (p<0.001, r=0.216)
spine X-ray is not available, the morphometry on chest X-ray has been proposed as a possible alternative for the diagnosis of VFs [8].

Our data showed moreover that the incidence of VFs was significantly higher in patients older both at the time of acromegaly diagnosis, at the time of diagnosis of incident VFs and at last follow-up. In an interesting way, we found a positive correlation (as showed in Fig. 3) between the age at acromegaly diagnosis and the age at the diagnosis of incident VFs, but also between the age at acromegaly diagnosis and at the age of the last follow-up visit, suggesting that the duration of follow-up is not dependent from the age of patients at the diagnosis of acromegaly (p=0.399) and as for consequence from the age of patients in starting cures and follow-up.

These data suggest that also the physiological process of aging may play a crucial role in the occurrence of VFs in older patients with acromegaly [42]. Moreover, in a recent case–control study, acromegaly patients aged over 65 years old showed more frequently musculoskeletal and bone diseases than no-acromegaly matched group (52% vs. 12%; 64% vs. 10%; P < 0.05) supporting that aging and acromegaly could affect both negatively bone health [43]. Osteoporosis is considered the most common metabolic disease in the elders with a prevalence of around 39% in study population [44]. Senile osteoporosis is a multifactorial disease, with a central role played by the high levels of PTH. In elderly subjects, hyperparathyroidism may be due to vitamin D deficiency [45] and to the chronic kidney disease. In fact, serum PTH values generally increase when estimated glomerular filtration rate falls below 60 mL/min/1.73 m2 [46].

However, we found a positive correlation between the length of the diagnostic delay and both the age at acromegaly diagnosis and the age at the last follow-up. A possible explanation of this finding may be that acromegaly patients with longer diagnostic delay are in this cohort affected more acromegaly-related comorbidities since the time of acromegaly diagnosis. In parallel, patients with more acromegaly related comorbidities were older at the time of last follow-up (as showed in supplementary table 1). These data may suggest that the acromegaly diagnostic delay may cause the occurrence of multiple acromegaly related comorbidities and, as for consequence, the presence of systemic comorbidities may represent a reason for older patients remaining in follow-up. Interestingly, only diagnostic delay and not age-related factors were significantly predicting incident VFs at multivariate analysis. The diagnostic delay in elderly acromegaly patients may be due to the overlap between the features of acromegaly and of the physiological ageing [47]. In a retrospective cohort of 57 newly diagnosed acromegalic patients aged over than 60 years, hypertension, glucose metabolism abnormalities, joint complaints and goiter were the most prevalent comorbidities [48], that typically occur with a high frequency in no acromegaly elderly individuals. In parallel, in this study we found a positive correlation between the diagnostic delay and the age of acromegaly patients at last follow-up.

In this study, we did not find a significant correlation between the occurrence of VFs and the biochemical status of acromegaly and the length of active disease. In this series, in fact, the number of patients with active disease at follow-up was very low, counting only fourteen out of the 172 enrolled patients (8.1%). Similarly, in this cohort of patients at the logistic regression we did not find a significant difference of length of active acromegaly disease among patients with and without incident VFs. Previous data in the literature on the effect of the length of active acromegaly had suggested that a longer period of active acromegaly was associated to an increased risk of incident vertebral fractures [14, 48]. A possible reason of this discrepancy may be due to the shorter duration of active acromegaly in patients with cured/controlled of acromegaly in this cohort. In fact, the large majority of patients reached the cure/control of acromegaly, with a median duration of active disease of 15 months (IQR: 13, range 6–30 months).

In previous reports, the duration of active disease ranged from 23 to 186 months [16, 27, 49]. As a consequence, the small number of patients with active acromegaly and short duration of active disease in this cohort may explain the absence of correlation with the occurrence of incidental vertebral fractures.

The main limitations of our study are the retrospective design, the low number of patients with active acromegaly disease, the lack of a control elderly population to rule out the impact of aging per se in our population.

In conclusion, our results showed for the first time that the diagnostic delay in acromegaly in a significant cause of skeletal fragility and vertebral fractures. Since these comorbidities are irreversible, our results underline that only a prompt and early diagnosis and treatment of acromegaly may be effective in protecting the patient from its life-long consequences, among which those affecting bone based on our data appear to be particularly time-sensitive.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s11102-022-01266-4.

Author contributions AG, LDM; Methodology: SC. Investigation: SC, AG, IG, MB, MV, AB; Formal analysis: SC; Writing—original draft preparation: SC, LDM, AG; Writing—review and editing: SC, LDM, IG, MRA, AG; Supervision: LDM, AG. All authors read and approved the final manuscript.

Funding Open access funding provided by Università Cattolica del Sacro Cuore within the CRUI-CARE Agreement. The study was not support by research grant.
Data availability  The data presented in this study are available on request from the corresponding author.

Declarations

Conflict of interest  The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this paper.

Ethical approval  The study was approved by local ethical committees. All procedures performed in the study were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by local Institutional Review Boards. All patients signed an informed consent before entering the study.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kasuki L, Rocha PDS, Lamback EB, Gadelha MR (2019) Determinants of morbidity and mortality in acromegaly. Arch Endocrinol Metab 63(6):630–637. https://doi.org/10.20945/2359-3997000000193

2. Chiloio S, Mirra F, Federico D, Giampietro A, Visconti F, Rossi L, Pontecorvi A, De Marinis L, Bianchi A (2020) The role of growth hormone receptor isoforms and their effects in bone metabolism and skeletal fragility. Protein Pept Lett 27(12):1260–1267. https://doi.org/10.2174/0929866527666200616151105

3. Kužma M, Killinger Z, Jackuliak P, Vaňuga P, Hans D, Binkley N, Payer J (2019) Pathophysiology of growth hormone secretion disorders and their impact on bone microstructure as measured by trabecular bone score. Physiol Res 68(2):S121–S129. https://doi.org/10.3354/physiores.934303

4. Bima C, Chiloio S, Mormando M, Piacentini S, Bracaccia E, Giampietro A, Tartaglione L, Bianchi A, De Marinis L (2016) Understanding the effect of acromegaly on the human skeleton. Expert Rev Endocrinol Metab 11(3):263–270. https://doi.org/10.1080/17446651.2016.1179108

5. Giustina A (2020) Acromegaly and vertebral fractures: facts and questions. Trends Endocrinol Metab 31(4):274–275. https://doi.org/10.1016/j.tem.2020.01.011

6. Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffeizzoni F, Cristiano A, Giampietro A, De Marinis L, Giustina A (2013) Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 98(8):3402–3410

7. Claessen KM, Kroon HM, Pereira AM, Appelman-Dijkstra NM, Verstegen MJ, Kloppenburg M, Hamdy NA, Biemarz NR (2013) Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J Clin Endocrinol Metab 98(12):4808–4815. https://doi.org/10.1210/jc.2013-2695

8. Frara S, Uygor MM, di Filippo L, Doga M, Losa M, Santoro S, Mortini P, Giustina A (2022) High Prevalence of Vertebral Fractures Associated with Preoperative GH Levels in Patients with recent Diagnosis of Acromegaly. J Clin Endocrinol Metab. https://doi.org/10.1210/cen/dgac183

9. Claessen KM, Mazziotti G, Biemarz NR, Giustina A (2016) Bone and joint disorders in acromegaly. Neuroendocrinology 103(1):86–95

10. Mazziotti G, Biagioli E, Maffeizzoni F, Spinello M, Serra V, Maroldi R et al (2015) Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab 100(2):384–394

11. Giustina A (2016) Acromegaly: reducing diagnostic delay. Recent Prog Med 107(8):450–451. https://doi.org/10.1701/2313.250704

12. Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K, Sahnoun-Fathallah M, Auriemma R, Diaoal AM, Hulting AL, Ferone D, Hana V Jr, Filipononi S, Sievers C, Nogueira C, Fajardo-Montañana C, Carvalho D, Hana V, Stall A, Jaffrin-Réa ML, Delemener B, Colao A, Brue T, Neiger SJMM, Zacharias E, Chanson P, Beckers A (2017) Acromegaly at diagnosis in 3173 patients from the Liege Acromegaly Survey (LAS) Database. Endocr Relat Cancer 24(10):505–518. https://doi.org/10.1530/ERC-17-0253

13. Caron F, Brue T, Raverot G, Tabarin A, Cailleux A, Delemener B, Renoult PP, Houchard A, Elaraki F, Chanson P (2019) Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study. Endocrine 131(1):120–129. https://doi.org/10.1007/s12001-018-1764-4

14. Esposito D, Ragnarsson O, Johannsson G, Olsson DS (2020) Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol 182(6):523–531. https://doi.org/10.1530/EJE-20-0019

15. Sisco J, van der Lely AJ (2021) Towards an Earlier Diagnosis of Acromegaly and Gigantism. J Clin Med 10(7):1363. https://doi.org/10.3390/jcm10071363

16. Mazziotti G, Canalies E, Giustina A (2010) Drug-induced oстеоропosis: mechanisms and clinical implications. Am J Med 123(10):877–884

17. Giustina A, Barkhouddarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Feda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersen S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimom I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S (2020) Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. https://doi.org/10.1007/s11154-020-09588-z

18. Melmed S, Bronstein MD, Chanson P, Kibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Lugger A, Clemmons DR, Giustina A (2018) A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552–561

19. Peixe C, Sánchez-García M, Grossman AB, Klibanski A, Bronstein MD, Marques P (2022) Elevated GH or IGF-1 levels do not always diagnose acromegaly. Growth Horm IGF Res 64:101467. https://doi.org/10.1016/j.ghir.2022.101467

20. Melmed S, Casanueva FF, Kibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JAH, Giustina A (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16(3):294–302. https://doi.org/10.1007/s11102-012-0420-x
21. Detomas M, Reuter M, Deutschbein T (2021) New developments and perspectives in acromegaly. Disch Med Wochenschr 146(15):950–954. https://doi.org/10.1055/a-1495-2715

22. de Azevedo OB, Araujo B, Dos Santos TM, Ongaratti BR, Rech CGSL, Ferreira NP, Pereira-Lima JFS, da Costa OM (2019) The acromegalic spine: fractures, deformities and spinopelvic balance. Pituitary 22(6):601–606. https://doi.org/10.1007/s11120-019-00991-7

23. Chilio S, Giampietro A, Frara S, Bima C, Donfrancesco F, Fleseriu CM, Pontecorvi A, Giustina A, Fleseriu M, De Marinis L, Bianchi A (2020) Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. J Clin Endocrinol Metab 105(3):dgz054. https://doi.org/10.1210/clinem/dgz054

24. Chilio S, Mormando M, Bianchi A, Giampietro A, Milardi D, Bima C, Grande G, Formenti AM, Mazzotti G, Pontecorvi A, Giustina A, De Marinis L (2018) Prevalence of morphometric vertebral fractures in “difficult” patients with acromegaly: update with biochemical outcomes after multimodal treatment. Endocrine 59(2):449–453. https://doi.org/10.1007/s12020-017-1391-5

25. Mazzotti G, Battista C, Maffezzoni F, Chilio S, Ferrante E, Principe N, Grasso L, Gatto F, Olivetti R, Arosio M, Barale M, Bianchi A, Cellini M, Chiodini I, De Marinis L, Del Sindaco G, Di Somma C, Ferlin A, Ghigo E, Giampietro A, Grotti S, Lavezzini E, Mantovani G, Morenghi E, Pivonello R, Porcello T, Procopio M, Pugliese F, Scillitani A, Lania AG (2020) Treatment of acromegalic osteopathy in real-life clinical practice: The Baac (Bone Active Drugs in Acromegaly) Study. J Clin Endocrinol Metab 105(9):dgaa363. https://doi.org/10.1210/clinem/dgaa363

26. Chilio S, Mazzotti G, Giampietro A, Bianchi A, Frara S, Mormando M, Pontecorvi A, Giustina A, De Marinis L (2018) Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. Pituitary 21(3):302–308. https://doi.org/10.1007/s11120-018-0873-7

27. Mazzotti G, Biagioli E, Maffeazzoni F, Spinello M, Serra V, Maroldi R, Floriani I, Giustina A (2015) Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab 100(2):384–394. https://doi.org/10.1210/jc.2014-2937

28. Hubina E, Lakatos P, Kovacs L, Szabolcs I, Racz K, Toth M, Szucs N, Gott MI (2004) Effects of 24 months of growth hormone (GH) treatment on serum carboxylated and undercarboxylated osteocalcin levels in GH-deficient adults. Calcif Tissue Int 75:54–59

29. Sugiyama T, Kawai S (2001) Carboxylation of osteocalcin may supports formation and activation of osteoclasts. Endocrinology 142(3):1201–1218. https://doi.org/10.1210/endo.2001-0282

30. Canalis E, Rydziel S, Delany AM, Varghese S, Jeffrey JJ (1995) Insulin-like growth factors inhibit interstitial collagenase synthesis in bone cell cultures. Endocrinology 136:1348–1354

31. Playford MP, Bicknell D, Bodmer WF, Macaulay VM (2000) Insulin-like growth factor-I regulates the location, stability, and transcriptional activity of β-catenin. Proc Natl Acad Sci 97:12103–12108

32. Krishnan V, Bryant HU, MacDougall OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116:1202–1209

33. Mochizuki H, Hakeda Y, Wakisaka N, Usui N, Akashi S, Sato T, Tanaka K, Kume-gawa M (1992) Insulin-like growth factor-I supports formation and activation of osteoclasts. Endocrinology 131:1075–1080

34. Niu T, Rosen CJ (2005) The insulin-like growth factor-I gene and osteoporosis: a critical appraisal. Gene 361:38–56

35. Cellini M, Biancome E, Mazza M, Trenti N, Ragucci P, Milani D, Ferrante E, Rossini Z, Lavezzini E, Sala E, Mantovani G, Arosio M, Fornari M, Balzarini L, Lania AG, Mazzotti G (2021) Vertebral fractures associated with spinal sagittal imbalance and quality of life in acromegaly: a radiographic study with EOS 2D/3D technology. Neuroendocrinology 111(8):775–785. https://doi.org/10.1159/000511811

36. Cangiano B, Giusti E, Premoli C, Soranna D, Vitale G, Grotti S, Cambria V, Mantovani G, Mungari R, Maifei P, Dassie F, Giampietro A, Chilio S, Tanda ML, Ippolito S, Cannavò S, Ragonese M, Zambon A, Persani L, Fatti LM, Scacchi M. “PRO-ACRO” study group on Motor Disability in Acromegaly, of the Italian Society of Endocrinology (SIE) (2022) Psychological complications in patients with acromegaly: relationships with sex,arthropathy, and quality of life. Endocrine. https://doi.org/10.1007/s12020-022-03106-8

37. di Filippo L, Formenti AM, Doga M, Pedone E, Rovere-Querini P, Giustina A (2021) Radiological thoracic vertebral fractures are highly prevalent in COVID-19 and predict disease outcomes. J Clin Endocrinol Metab 106(2):e602–e614. https://doi.org/10.1210/clinem/dgaa738

38. Kasuki L, Antunes X, Lamback EB, Gadelia MR (2020) Acromegaly: update on management and long-term morbidities. Endocrinol Metab Clin North Am 49(3):475–486. https://doi.org/10.1016/j.ecl.2020.05.007

39. SRLs. J Clin Endocrinol Metab 105(3):dgaa363. https://doi.org/10.1210/clinem/dgaa363

40. Duan L, Yang S, Wang LJ, Zhang Y, Li R, Yang H, Zhao Y, Du H, Zhai X, Gong F, Pan H, Zhu H, Xia W (2021) The negative impacts of acromegaly on bone microstructure not fully reversible. Front Endocrinol (Lausanne) 12:738895. https://doi.org/10.3389/fendo.2021.738895.eCollection2021

41. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357(9):905–916

42. Chilio S, Bianchi A, Giampietro A (2019) De Marinis L Somatotrophic Axis in Human Aging. In: Huhtaniemi I, Martini L (eds) Encyclopedia of Endocrine Diseases, 2nd edn. Academic Press, Oxford, pp 700–707

43. Gagliardi I, Chilio S, Vallillo M, Bondanelli M, Volpato S, Giampietro A, Bianchi A, De Marinis L, Zarelli MC, Ambrosio MR (2021) Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study. BMC Geriatr 21:598

44. Salari N, Darvishi N, Bartina Y, Shohaimi S, Mohammadi M (2021) Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis. J Orth Surg Res 16(1):669. https://doi.org/10.1186/s13018-021-02821-8

45. Bilezikian JP, Formenti AM, Adler RA, Binkley N, Bouillon R, Lararareti-Castro M, Marccoci C, Napoli N, Rizzoli R, Giustina A (2021) Vitamin D: dosing, levels, form, and route of administration: does one approach fit all? Rev Endocr Metab Disord 22(4):1201–1218. https://doi.org/10.1007/s11154-021-09693-7

46. Hampson G, Elder GJ, Cohen-Solal M, Abrahamsson B (2021) A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. Endocrine 73(3):509–529. https://doi.org/10.1007/s12020-021-02735-9

47. Ambrosio MR, Gagliardi I, Chilio S, Ferreira AG, Bondanelli M, Giampietro A, Bianchi A, Marinis L, Fleseriu M, Zarelli MC
(2020) Acromegaly in the elderly patients. Endocrine 68(1):16–31. https://doi.org/10.1007/s12020-020-02206-7

48. Colao A, Pivonello R, Spinelli L, Auriemma RS, Galdiero M, Vitale G, De Leo M, Lombardi G (2007) A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients. J Endocrinol Invest 30(6):497–506

49. Mormando M, Nasto LA, Bianchi A, Mazziotti G, Giampietro A, Pola E, Pontecorvi A, Giustina A, De Marinis L (2014) GH receptor isoforms and skeletal fragility in acromegaly. Eur J Endocrinol 171(2):237–245. https://doi.org/10.1530/EJE-14-0205

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.